Sienna Cancer Diagnostics Ltd. announced the appointment of Helen Fisher as an Independent Non- Executive Director and Chair of the Audit and Risk Committee, effective 28 March 2018. Previously a partner at Deloitte for 10 years, Ms. Fisher has an exemplary track record, including leading Deloitte Australia's Life Sciences Industry team and advising many Life Sciences and Biotechnology companies. In July 2017, Ms. Fisher established a new global Life Sciences fund, Bio Capital Impact Fund, investing in disruptive, high-growth Life Science and Biotechnology companies.